Limited Dose-Effect Relationship of Adenosine for Detection of Atrioventricular Nodal Duality in Patients with Supraventricular Tachycardias

Christiana Schernthaner  Maximilian Pichler  Bernhard Strohmer

Department of Cardiology, Salzburger Landeskliniken, Paracelsus Private Medical University, Salzburg, Austria

Key Words
Adenosine · Atrioventricular nodal duality · Atrioventricular nodal reentrant tachycardia · Supraventricular tachycardia

Abstract
Objective: The purpose of the study was to test the dose-effect relationship of adenosine for the diagnosis of dual atrioventricular (AV) nodal physiology in patients with palpitations. Subjects and Methods: The study population consisted of 57 patients (mean age 50 ± 14 years; 36 females, 21 males) with palpitations related to supraventricular tachycardia. Adenosine was injected as a bolus to unmask dual AV nodal physiology by a PR jump on surface ECG (defined as a sudden increase by ≥ 50 ms measured from the onset of the P-wave to the R-wave between two consecutive sinus beats). According to a stepwise clinical approach, adenosine was administered as bolus in incremental dosages (6 mg followed by 12 mg, if necessary up to 18 mg). Once a PR jump ≥ 50 ms or a high-grade AV block was noted on surface ECG, the injection was stopped at that dose. Results: A significant PR jump was noted after injection of 6 mg (n = 21, 99 ± 30 ms) or 12 mg (n = 13, 94 ± 35 ms), but not after 18 mg (n = 4, 35 ± 10 ms) adenosine. Provocation of temporary first-grade AV block (n = 13) was associated with the longest increment of PR interval, whereas high-grade AV block (n = 36) produced a significantly shorter PR jump (105 ± 35 vs. 65 ± 40 ms, p = 0.0024). Electrophysiological study and ablation were performed in 37 highly symptomatic patients. AV nodal reentrant tachycardia was diagnosed in 33 patients and orthodromic AV reentrant tachycardia in 4 patients. Conclusion: The adenosine test was characterized by a reverse dose-effect relationship as far as identification of AV nodal duality was concerned.

Introduction

The most frequent diagnosis in patients who present with paroxysmal palpitations to an outpatient clinic is atrioventricular nodal reentrant tachycardia (AVNRT) [1]. Since AVNRT depends on the presence of dual atrioventricular (AV) nodal pathways, evidence of dual AV nodal physiology makes the diagnosis of AVNRT very likely [2]. Previous studies demonstrated that administration of adenosine triphosphate or adenosine during sinus rhythm helps to identify the mechanism of supraventricular tachycardia (SVT) in patients presenting with palpitations [3–9]. Moreover, both short-acting drugs have been used to differentiate AVNRT from AV reentrant tachycardia (AVRT) [5, 8]. The use of this simple noninvasive test may help select patients for early referral.
to invasive electrophysiological (EP) evaluation. The purpose of this study was to test the dose-effect relationship of adenosine for the diagnosis of dual AV nodal physiology in patients presenting with palpitations [10].

Subjects and Methods

Subjects
The study comprised a total of 57 consecutive patients (21 men, 36 women; age 50 ± 14 years) who were referred to the outpatient clinic of our institution with palpitations or syncope suggestive of paroxysmal SVT. A documented index ECG was present in 41 patients showing a narrow QRS tachycardia, which was inconclusive with respect to the underlying mechanism in most of the cases. None of the patients showed a delta wave on the 12-lead surface ECG during sinus rhythm. All patients had a structurally normal heart except one, who presented with moderate aortic valve regurgitation. The baseline characteristics of the patients are shown in Table 1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>50 ± 14</td>
</tr>
<tr>
<td>Male/female, n (%)</td>
<td>21/36 (37/63)</td>
</tr>
<tr>
<td>Structural heart disease, n (%)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Ejection fraction ≥60%, n (%)</td>
<td>57 (100)</td>
</tr>
<tr>
<td>Duration of arrhythmia, years</td>
<td>10 ± 12</td>
</tr>
<tr>
<td>Palpitations/syncope, n (%)</td>
<td>53/4 (93/7)</td>
</tr>
<tr>
<td>Antiarrhythmic medication, n (%)</td>
<td>45 (79)</td>
</tr>
<tr>
<td>Class I</td>
<td>23 (40)</td>
</tr>
<tr>
<td>β-Blockers</td>
<td>16 (28)</td>
</tr>
<tr>
<td>Class III</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Class IV</td>
<td>3 (5)</td>
</tr>
</tbody>
</table>

1 Values are expressed as mean ± standard deviation.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
</table>

Adenosine Test
The adenosine test was performed as a bedside test during sinus rhythm. All patients gave informed consent to this specific pharmacological testing. Adenosine (3 mg/ml; Ebewe Pharma, Unterach, Austria) was injected through an antecubital vein as a rapid bolus, followed by a 20-ml flush of normal saline. A 12-lead surface ECG was recorded simultaneously with a paper speed of 25 mm/s. According to our stepwise clinical protocol, the initial dose was 6 mg adenosine. If a PR jump ≥50 ms was noted on surface ECG or a third-degree AV block occurred, the injection was stopped. In case of no response to the first dose, a bolus of 12 mg adenosine was administered after 5 min. Only those patients who demonstrated neither a significant PR jump nor a high-grade AV block after injection of 12 mg adenosine received an 18-mg bolus of adenosine intravenously after a waiting period of another 5 min. Furthermore, the occurrence of AV nodal echo beats or AV reentrant echo beats was evaluated based on the definition of previous studies [4, 5, 8]. The results were reviewed and graded by two independent electrophysiologists.

EP Study
Overall, 37 patients underwent invasive evaluation after written informed consent. An EP study was performed in those patients who were highly symptomatic and/or suffered from frequent recurrences of palpitations or arrhythmias. Three quadrupolar electrode catheters were introduced through both femoral veins and positioned in the right atrium, in the His-bundle position and in the apical right ventricle. A luminal decapolar catheter was introduced from the right internal jugular vein into the coronary sinus. Standard EP criteria were used for defining dual AV nodal physiology, AVNRT or AVRT [11]. If AVNRT or AVRT were not inducible with incremental or decremental pacing from the right atrium or ventricle, orciprenaline was administered. After confirmation of the correct diagnosis by various pacing techniques, radiofrequency ablation was performed.

Statistics
The validity of the test was analyzed by determining the sensitivity (conditional probability that the adenosine bedside test will be positive if the condition, i.e. dual AV nodal physiology, is present during EP study), specificity (conditional probability that the adenosine test will be negative if the condition, i.e. dual AV nodal physiology, is absent during EP study) as well as the positive and negative predictive value for all patients who underwent EP testing. Statistical analysis was performed by unpaired t test. A p value ≤0.05 was considered statistically significant. Data are expressed as mean ± standard deviation.

Results
Adenosine Test
Of the 57 patients, a significant PR jump (mean 99 ± 30 ms) was provoked in 21. Abrupt occurrence of third-degree AV block was noticed in 6 patients. In another 3, SVT was triggered by administration of 6 mg adenosine and no further adenosine testing was performed thereafter. Of the remaining 27 patients, a significant PR increment (mean PR jump 94 ± 35 ms) was observed in 13 and 9 developed a transient high-grade AV block. Finally, only 5/27 patients remained in the study to undergo a bolus injection of 18 mg adenosine. One patient refused further adenosine bedside testing because of the transient nonspecific discomfort related to this drug. Consequently, only 4/27 patients received 18 mg adenosine. No significant PR jump was observed in any of the 4 patients. The individual responses were a PR increment of 40 ms in 3 subjects and a PR increment of 20 ms in 1 patient (mean PR increment 35 ± 10 ms).

Among all the patients, drug-induced temporary first-degree AV block was noticed in 13 (23%), whereas abrupt
high-grade AV block was observed in 36 (63%). Provocation of temporary first-grade AV block was associated with the longest increment of PR interval, whereas high-grade AV block was associated with a shorter PR prolongation (PR jump 105 ± 35 ms vs. 65 ± 40 ms, respectively; \( p = 0.0024 \)). Overall, a positive adenosine test was observed in 34 (60%) patients who demonstrated AV nodal duality at a mean dosage of 8 ± 3 mg. A negative adenosine test was noticed in 23 (40%) patients. The mean adenosine dose leading instantaneously to high-grade AV block without any evidence of AV nodal duality was 9 ± 4 mg. Interestingly, there was no significant difference between the adenosine dosages eliciting dual AV nodal physiology or high-grade AV block (8 ± 3 mg vs. 9 ± 4 mg, respectively).

Of the 37 patients that underwent an EP study, a positive adenosine bedside test was noted in 31. A significant PR jump occurred after injection of 6 mg adenosine (PR jump 95 ± 38 ms) in 15 patients and after injection of 12 mg adenosine (PR jump 83 ± 43 ms) in 16 patients. The PR prolongation after bolus application of 18 mg adenosine was 30 ± 14 ms. First-degree AV block was associated with longer PR jumps in 11 patients, when compared to the PR increments associated with occurrence of high-grade AV block in 22 patients (PR jump 106 ± 36 ms vs. 73 ± 41 ms, respectively; \( p = 0.029 \)). Of note, AV nodal duality was not identified in 6 (16%) patients with the help of the adenosine test but with EP stimulation. Four of these patients with a ‘false’ negative adenosine test demonstrated high-grade AV block only, whereas the other 2 patients showed no PR prolongation at all despite a dose of 18 mg adenosine.

The results of the adenosine bedside test are summarized in figure 1. Representative ECG examples are shown in figure 2. AV nodal echo beats were noted in 3 patients and AV reentrant echo beats in 2 patients. Adenosine triggered SVT in 4 patients, but in none of the cases atrial fibrillation. Otherwise, adenosine was tolerated without adverse events.

**Discussion**

The results of this study demonstrate a limited dose-effect relationship of adenosine when used for diagnosis of AV nodal duality in patients with symptomatic SVT. Bolus injection of up to 12 mg adenosine provoked a significant PR jump on surface ECG, whereas 18 mg adenosine yielded no additional diagnostic information. Evidence exists from pharmacological studies that the antegrade fast pathway is more sensitive to the effects of adenosine than the slow pathway [3]. If the fast pathway is blocked selectively with adenosine, conduction occurs over the slow pathway, which manifests itself as an in-
crease in the PR interval. At higher doses, however, the fast pathway is blocked less selectively and high-grade AV block occurs. In this case, both AV nodal inputs are blocked together and discrimination of the two pathways is no longer possible on surface ECG.

The observation that the maximum dose of the drug was not effective to provoke AV block in a few patients has been attributed to the increased sympathetic stimulation caused by adenosine itself. In order to avoid unpleasant and potentially harmful side effects, we recommend avoiding administration of such high adenosine doses. Repetition of the diagnostic bedside test at another time or after a longer resting period is considered to be more effective than adenosine doses exceeding 12 mg. In clinical practice, one should always try to administer adenosine at the lowest dose possible to unmask dual AV nodal pathways. The commonly used starting dose of 6 mg adenosine may already result in high-grade AV block due to blockade of both pathways simultaneously. In order to improve the sensitivity of the test, we suggest that a starting dose as low as 3 mg adenosine might be appropriate in some cases. Moreover, smaller dose increments (e.g. 3 mg adenosine) could be helpful to identify silent dual AV nodal physiology.

Belhassen et al. [3–6] evaluated the effect of adenosine triphosphate during sinus rhythm as a valuable tool to diagnose dual AV nodal physiology as well as to differentiate AVNRT from AVRT. In their study, the mean adenosine triphosphate dose was 19.3 ± 8.5 mg for diagnosing dual AV nodal physiology and 15.6 ± 6 mg for differentiating between both types of SVT [3, 5]. Moro et al. [12] reported a dose-related efficacy of adenosine triphosphate for termination of spontaneous SVTs. Side effects, such as sinus pauses and bradycardia following termination of the arrhythmia, were directly correlated with the dose employed. Other investigators focused their interest on the pharmacological effects of the very short-acting drug adenosine [7, 8, 13]. Burkart et al. [13] used a mean dose of 7.1 ± 3.9 mg adenosine to block the AV node while pacing the atrium. Tebbenjohanns et al. [7] investigated the value of the adenosine test in 37 patients and found that the mean dose to show dual AV nodal physiology or to produce AV block was 10.3 mg adenosine. Toal et al. [8] tested a single dose of 12 mg adenosine and reported a sensitivity of 74% and a specificity of 94%. In accordance with the latter results, we found a sensitivity of 82% and a specificity of 100%, confirming the observation that higher doses of adenosine (i.e. more than 12 mg) do not improve the diagnostic value of this simple non-
Dose-Effect Relationship of Adenosine for Detection of AV Nodal Duality

Invasive test. The incidence of AV nodal echo beats was about 5% in our study, which is similar to that reported by Toal et al. [8] but definitely lower than that reported by Belhassen et al. [3] (48%) or Tebbenjohanns et al. [7] (23%). AV reentrant echo beats were seen in 2 of the 4 patients with a concealed accessory pathway.

A major limitation of this study is the small number (4) of patients receiving 18 mg adenosine. However, in the light of a clinically driven study there was no reason to administer higher doses of adenosine once dual AV nodal physiology or high-grade AV block were elicited by lower dosages. Another limitation was that a relatively small number of patients (37) with AVRT were included in our study. None of our patients with AVRT presented dual AV nodal physiology in addition to the accessory pathway. However, the clinician has to keep in mind that dual AV nodal pathways may be present in patients with AVRT in up to 40% resulting in double tachycardias [14]. Although we did not observe any adverse event beside the typical vasodilatory effects of the drug, application of adenosine – particularly in higher doses – should only be performed under specific precautions and in an environment where resuscitation is feasible. Serious complications and life-threatening conditions despite the very short half-life of the drug have been reported [15, 16].

Conclusion

The results of this study demonstrate that adenosine has a limited dose-effect relationship in unmasking AV nodal duality. Thus, the lowest dose possible to get the differential effect on dual AV nodal pathways is preferred. In the present study, a bolus of 6–12 mg adenosine turned out to be effective for selective blockade of the fast pathway, manifesting itself in a significant PR jump on the surface ECG. Consequently, the induction of first-grade AV block was more predictive of the presence of dual AV nodal physiology than high-grade AV block. The adenosine bedside test is a safe and useful measure for detection of dual AV nodal physiology during normal sinus rhythm with a high sensitivity and specificity.

References


9 Strohmer B: Rate-dependent left bundle branch block unmasked by adenosine. Int J Cardiol 2005;103:219–220.


